Preliminary Injunction Granted to Enforce Revvity’s Rights and Cloud Software Group’s Obligations Related to Spotfire Software
02 Aprile 2024 - 12:00PM
Business Wire
Today, Revvity, Inc. (NYSE: RVTY) announced that the
Massachusetts Superior Court has granted a preliminary injunction
compelling Cloud Software Group (CSG) to comply with its
contractual obligations under its strategic partner agreements with
Revvity, including an order to cease all marketing, selling and
support activities in Revvity’s exclusive markets and to continue
delivering maintenance services to Revvity in relation to its
Spotfire® software.
This decision comes after Revvity filed a lawsuit against CSG,
alleging unfair business practices and breach of contract. The
preliminary injunction ensures uninterrupted service to Revvity and
its customers of Spotfire software, safeguarding their operational
continuity and service quality. Revvity remains dedicated to
upholding the highest standards of service delivery and customer
satisfaction that it has been delivering to Spotfire customers for
over a decade.
"We are pleased with the court's decision to grant the
preliminary injunction," said Kevin Willoe, SVP and general manager
at Revvity Signals Software. "This ruling underscores the strength
of our legal position in this matter and, more importantly, the
importance of Revvity’s domain knowledge and expertise in serving
our valued customers as they advance their science. Revvity remains
steadfast in our commitment to providing unparalleled service
excellence."
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is
a call to action. Revvity provides health science solutions,
technologies, expertise and services that deliver complete
workflows from discovery to development, and diagnosis to cure.
Revvity is revolutionizing what’s possible in healthcare, with
specialized focus areas in translational multi-omics technologies,
biomarker identification, imaging, prediction, screening, detection
and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000
employees, Revvity serves customers across pharmaceutical and
biotech, diagnostic labs, academia and governments. It is part of
the S&P 500 index and has customers in more than 190
countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube,
Facebook and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240402555445/en/
Investor Relations: Steve Willoughby
steve.willoughby@revvity.com Corporate Communications: Fara
Goldberg fara.goldberg@revvity.com
Grafico Azioni Revvity (NYSE:RVTY)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Revvity (NYSE:RVTY)
Storico
Da Dic 2023 a Dic 2024